AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3421598 — intervention group
Group type: COMPARATOR
Intervention: Matched group of inmates (control)
Number of subjects: 44
Study 31126286 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS + LLIN
Number of subjects: 0
Study 31126286 — intervention group
Group type: COMPARATOR
Intervention: IRS
Number of subjects: 0
Study 31126286 — intervention group
Group type: COMPARATOR
Intervention: LLIN
Number of subjects: 0
Study 31126286 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28851065 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 270 μg kg‐1 rFVIIa
Number of subjects: 0
Study 28851065 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 3×90 μg kg‐1 rFVIIa
Number of subjects: 0
Study 25285748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT)
Number of subjects: 428
Study 25285748 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 428
Study 25285748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT) in patients with EFs ranging from 25% to 45%
Number of subjects: 428
Study 25285748 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO2
Number of subjects: 428
Study 22949122 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 94
Study 22949122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ibuprofen
Number of subjects: 94
Study 21448073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen (50 mg) intravenously
Number of subjects: 60
Study 21448073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL of 0.9% NaCL) intravenously
Number of subjects: 60
Study 18279521 — intervention group
Group type: EXPERIMENTAL
Intervention: QIRC strategy (experimental group)
Number of subjects: 672
Study 18279521 — intervention group
Group type: COMPARATOR
Intervention: Normal practice environment (control group)
Number of subjects: 672
Study 16023828 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell activity in patients with major depressive disorder
Number of subjects: 25
Study 16023828 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of interleukin‐6 (IL‐6) in patients with major depressive disorder
Number of subjects: 25
Study 16023828 — intervention group
Group type: COMPARATOR
Intervention: Natural Killer (NK) cell activity in controls
Number of subjects: 25
Study 16023828 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of interleukin‐6 (IL‐6) in controls
Number of subjects: 25
Study 12830447 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD) with the Fresenius 2008H machine and Service Deionization Tank (SDI) water treatment system
Number of subjects: 20
Study 12830447 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hemodialysis (HD)
Number of subjects: 20
Study 10854552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy (BOAI)
Number of subjects: 18
Study 9086690 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus aerobic training
Number of subjects: 128
Study 9086690 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus strength training
Number of subjects: 128
Study 9086690 — intervention group
Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 128
Study 9086690 — intervention group
Group type: EXPERIMENTAL
Intervention: diet combined with aerobic and strength training
Number of subjects: 128
Study 8464671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg) aerosolized every 6 hours starting on the first day of intubation
Number of subjects: 38
Study 8464671 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosolized every 6 hours starting on the first day of intubation
Number of subjects: 38
Study 8464671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 38
Study 31268250 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 5 mg/day
Number of subjects: 80
Study 31268250 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 50 mg/day
Number of subjects: 80
Study 31268250 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 150 mg/day
Number of subjects: 80
Study 31268250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30572911 — intervention group
Group type: EXPERIMENTAL
Intervention: PCG‐lncRNA signature
Number of subjects: 233
Study 27010201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma foot massage
Number of subjects: 57
Study 24533608 — intervention group
Group type: EXPERIMENTAL
Intervention: DBCare
Number of subjects: 35
Study 24533608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 23091096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment (chemotherapy every 14 days)
Number of subjects: 568
Study 23091096 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (chemotherapy every 21 days)
Number of subjects: 568
Study 20303095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 20
Study 20303095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17997459 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (50 mg instillation)
Number of subjects: 404
Study 17997459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 17997459 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (recurrences)
Number of subjects: 404
Study 17997459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (recurrences)
Number of subjects: 404
Study 16333652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.62 g/kg alcohol
Number of subjects: 30
Study 16333652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 30
Study 16333652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g/kg)
Number of subjects: 30
Study 12893041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet stance behavior in elderly adults
Number of subjects: 20
Study 12893041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet stance behavior in young adults
Number of subjects: 20
Study 11082368 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 0
Study 11082368 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 0
Study 11082368 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic blood cardioplegia
Number of subjects: 0
Study 11082368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 0
Study 11082368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood with warm reperfusion
Number of subjects: 0
Study 11082368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antegrade and retrograde cardioplegia
Number of subjects: 0
Study 11082368 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 0
Study 8776965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adrenalectomy for Cushing's syndrome
Number of subjects: 6
Study 8776965 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy for other adrenal tumors
Number of subjects: 6
Study 8776965 — intervention group
Group type: COMPARATOR
Intervention: Open adrenalectomy for Cushing's syndrome
Number of subjects: 6
Study 1281362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH; Sandoparin) administered once daily subcutaneously at a fixed dosage
Number of subjects: 216
Study 1281362 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 administered intravenously
Number of subjects: 216
Study 1281362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 216
Study 1281362 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 216
Study 1281362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Dextran 70
Number of subjects: 216
Study 3974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and constant weight
Number of subjects: 21
Study 3974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive and weight loss
Number of subjects: 21
Study 3974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and weight loss
Number of subjects: 21
Study 3974451 — intervention group
Group type: COMPARATOR
Intervention: Inactive and constant weight (control)
Number of subjects: 21
Study 31533277 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg dose of VLP vaccine
Number of subjects: 40
Study 31533277 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 µg dose of VLP vaccine
Number of subjects: 40
Study 31533277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30397707 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 66
Study 30397707 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 66
Study 26164350 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (2 sessions per week for 8 weeks)
Number of subjects: 40
Study 26164350 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 40
Study 25580784 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVS naphthalan for OLP
Number of subjects: 18
Study 25580784 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVS naphthalan for RAS
Number of subjects: 18
Study 25580784 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone for RAS (Control)
Number of subjects: 18
Study 22226929 — intervention group
Group type: EXPERIMENTAL
Intervention: firategrast 900 mg or 1200 mg
Number of subjects: 343
Study 22226929 — intervention group
Group type: EXPERIMENTAL
Intervention: firategrast 600 mg
Number of subjects: 343
Study 22226929 — intervention group
Group type: EXPERIMENTAL
Intervention: firategrast 150 mg
Number of subjects: 343
Study 22226929 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 343
Study 20359274 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 90
Study 20359274 — intervention group
Group type: COMPARATOR
Intervention: Paraffin pellets
Number of subjects: 90
Study 17998087 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire plus invitation letter
Number of subjects: 270
Study 17998087 — intervention group
Group type: COMPARATOR
Intervention: Control group (invitation letter only)
Number of subjects: 270
Study 15889358 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1000 mg 3 times per day) for patients with positive urinary antigen test results
Number of subjects: 219
Study 15889358 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg 2 times per day) for patients with negative urinary antigen test results
Number of subjects: 219
Study 12479768 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized HRQL assessments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30)
Number of subjects: 214
Study 9793914 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion technique
Number of subjects: 288
Study 9793914 — intervention group
Group type: COMPARATOR
Intervention: Contact technique
Number of subjects: 288
Study 8592955 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic use
Number of subjects: 523
Study 8592955 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical physical activity
Number of subjects: 523
Study 8592955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Current cigarette smoking
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Current leisure-time physical activity
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Dietary calcium intake
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D use
Number of subjects: 523
Study 8592955 — intervention group
Group type: COMPARATOR
Intervention: Caffeine intake
Number of subjects: 523
Study 2696507 — intervention group
Group type: EXPERIMENTAL
Intervention: IV labetalol, 0.25 mg/kg
Number of subjects: 24
Study 2696507 — intervention group
Group type: EXPERIMENTAL
Intervention: IV labetalol, 0.75 mg/kg
Number of subjects: 24
Study 2696507 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 24
Study 18493 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day clobazam (HR 376)
Number of subjects: 34
Study 18493 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/day diazepam
Number of subjects: 34
Study 31727662 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobarrier
Number of subjects: 0
Study 31727662 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 0
Study 28678392 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 95
Study 28678392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 26214167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active movement coordination with a confederate in a 2-handed sawing task
Number of subjects: 2
Study 26214167 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdependent self-construals (typical of Asian cultures)
Number of subjects: 2
Study 23099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Postradiation cisplatin and vincristine plus CCNU
Number of subjects: 379
Study 23099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Postradiation cisplatin and vincristine plus cyclophosphamide
Number of subjects: 379
Study 23099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (2340 cGy craniospinal and 5580 cGy posterior fossa)
Number of subjects: 379
Study 23099653 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 379
Study 21611972 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) intake (24%, n = 26)
Number of subjects: 47
Study 21611972 — intervention group
Group type: COMPARATOR
Intervention: Normal protein (NP) intake (18%, n = 21)
Number of subjects: 47
Study 19387874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention + Metformin (1500 g daily)
Number of subjects: 25
Study 19387874 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 25
Study 16711496 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (0.5% ropivacaine, 20 mL, plus continuous infusion of 5 mL/h)
Number of subjects: 0
Study 16711496 — intervention group
Group type: COMPARATOR
Intervention: Single-dose sciatic nerve block (20 mL of 0.5% ropivacaine)
Number of subjects: 0
Study 14709300 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% solution (Voltaren Ophthalmic)
Number of subjects: 34
Study 14709300 — intervention group
Group type: COMPARATOR
Intervention: Topical ketorolac tromethamine 0.5% solution (Acular)
Number of subjects: 34
Study 10963923 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from coworkers and supervisors
Number of subjects: 134
Study 10963923 — intervention group
Group type: EXPERIMENTAL
Intervention: Job efficacy
Number of subjects: 134
Study 10963923 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in a methadone clinic
Number of subjects: 134
Study 10963923 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of clients with HIV/AIDS
Number of subjects: 134
Study 10963923 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 134
Study 9036608 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF therapy alone (group 1)
Number of subjects: 63
Study 9036608 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF therapy plus antibacterial drugs (group 2)
Number of subjects: 63
Study 9036608 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 63
Study 1480446 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 64
Study 1480446 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 64
Study 3979723 — intervention group
Group type: COMPARATOR
Intervention: 10 g protein meal
Number of subjects: 35
Study 3979723 — intervention group
Group type: COMPARATOR
Intervention: 20 g protein meal
Number of subjects: 35
Study 3979723 — intervention group
Group type: COMPARATOR
Intervention: Gastric pH maintained at 4.5
Number of subjects: 35
Study 3979723 — intervention group
Group type: COMPARATOR
Intervention: Gastric pH allowed to decrease
Number of subjects: 35
Study 31102823 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution (gentamicin 7 mg/ml + cefazolin 12 mg/ml + heparin 3500 IU/ml)
Number of subjects: 127
Study 31102823 — intervention group
Group type: COMPARATOR
Intervention: Lock solution with TauroLock-Hep500 (taurolidine citrate 4% + heparin 500 IU/ml)
Number of subjects: 127
Study 29534661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1 cycle at 1.3 mg/m2), methylprednisolone (500 mg/kg), 7 sessions of plasmapheresis, antithymocyte globulin (3-5 mg/kg/day for 10 days), rituximab (2 doses at 375 mg/m2)
Number of subjects: 10
Study 29534661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment
Number of subjects: 10
Study 27187725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention via conference call (CBC)
Number of subjects: 61
Study 27187725 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention via conference call (BAC)
Number of subjects: 61
Study 27187725 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care (CG)
Number of subjects: 61
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 µg·kg(‐1)·min(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6-1.0 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 26814104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4-0.8 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study 22830927 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Papilla Gown
Number of subjects: 145
Study 22830927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gown only
Number of subjects: 145
Study 22830927 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 145
Study 22830927 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 145
Study 21680720 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells administered intradermally (10 million cells, once every 2 weeks for 4 administrations)
Number of subjects: 10
Study 21680720 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered dendritic cells
Number of subjects: 10
Study 21680720 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study 18945593 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (no psychotic or negative symptoms, living independently, GAF (f)>59, working or studying)
Number of subjects: 265
Study 18945593 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutionalization (either at hospital or supported housing)
Number of subjects: 265
Study 18945593 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of continuous illness course
Number of subjects: 265
Study 16536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 1522
Study 16536764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1522
Study 12669389 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 12669389 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 0
Study 12669389 — intervention group
Group type: COMPARATOR
Intervention: Treatment methods from randomized trials
Number of subjects: 0
Study 12669389 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine
Number of subjects: 0
Study 11595472 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT (20 mg omeprazole + 2 x 250 mg clarithromycin + 2 x 500 mg tinidazole for 7 days)
Number of subjects: 320
Study 11595472 — intervention group
Group type: COMPARATOR
Intervention: OAM (20 mg omeprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg metronidazole for 7 days)
Number of subjects: 320
Study 11595472 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC (40 mg pantoprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg clarithromycin for 7 days)
Number of subjects: 320
Study 11595472 — intervention group
Group type: COMPARATOR
Intervention: RBC-C (2 x 400 mg ranitidin bismuth citrate + 2 x 500 mg clarithromycin for 14 days)
Number of subjects: 320
Study 11595472 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM (2 x 30 mg lansoprazole + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Number of subjects: 320
Study 11595472 — intervention group
Group type: COMPARATOR
Intervention: RBC-CM (2 x 400 mg ranitidin bismuth citrate + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Number of subjects: 320
Study 9402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with three drugs
Number of subjects: 21
Study 9402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to VacA
Number of subjects: 21
Study 9402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to CagA
Number of subjects: 21
Study 8428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-port intermittent nebulization (CN)
Number of subjects: 21